Tie2 receptor activation for glaucoma

Abstract

This invention relates to the production and genotyping of mice lacking both Angiopoietin 1 and Angiopoietin 2. This invention also relates to the use of Tie2 receptor activation for treatment of open angle glaucoma, congenital glaucoma and cystic kidney disease, and more specifically to the use of angiopoietin 1 recombinant proteins, peptides, VE-PTP phosphatase inhibitors, and Tie2-peptomimetics to improve lymphatic drainage in the Schlemm's canal and corneal limbal lymphatic system for open angle glaucoma and congenital glaucoma patients, and to slow and/or reduce the growth of cysts in patients with cystic kidney disease.

What is claimed is: 
     
         1 . A method of treating a patient having open angle glaucoma, congenital glaucoma or cystic kidney disease, or for improving ocular lymphatic drainage in the patient comprising administering to the patient a pharmaceutical composition comprising one or more agents capable of TIE2 receptor activation, one or more of angiopoietin-1 recombinant proteins, peptides, VE-PTP phosphatase inhibitors, and/or Tie2-peptidomimetics. 
     
     
         2 .- 7 . (canceled) 
     
     
         8 . A conditional Angiopoeitin 2 knockout allele. 
     
     
         9 .- 10 . (canceled) 
     
     
         11 . A method for treatment of cystic kidney disease in a subject in need thereof, comprising administering to the subject an effective dosage amount of a pharmaceutical composition comprising one or more Tie2 receptor activating agents. 
     
     
         12 . (canceled)